What's Happening?
Harbour BioMed, a global biopharmaceutical company, has appointed Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation. Dr. Xie will be based in Shanghai and will report directly to Dr. Jingsong Wang, the company's
Founder, Chairman, and CEO. With over 25 years of experience in the biopharmaceutical industry, Dr. Xie previously held leadership roles at Bristol Myers Squibb and Merck. Her new role will involve leading Harbour BioMed's global external innovation strategy in immunology, managing strategic collaborations, and overseeing activities at the company's innovation lab in Beijing.
Why It's Important?
Dr. Jenny Xie's appointment is a strategic move by Harbour BioMed to bolster its research and development capabilities in immunology. Her extensive experience in drug discovery and development is expected to drive innovation and strengthen the company's pipeline of novel antibody therapeutics. This appointment underscores Harbour BioMed's commitment to advancing its R&D efforts and enhancing its global collaboration initiatives. The company's focus on immunology and oncology positions it to make significant contributions to the development of next-generation therapeutic antibodies, potentially transforming patient care in these critical areas.
